KAMADA LTD Form 6-K September 04, 2014

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the Month of September, 2014

Commission File Number 001-35948

Kamada Ltd. (Translation of registrant's name into English)

7 Sapir St. Kiryat Weizmann Science Park

P.O Box 4081 Ness Ziona 74140 Israel (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F T Form 40-F "

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby

Yes " No T

furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_

This Form 6-K is being incorporated by reference into the Registrant's Form S-8 Registration Statement File No. 333-192720.

## Edgar Filing: KAMADA LTD - Form 6-K

The following exhibit is attached	The	foll	owing	exhibit	is	attached
-----------------------------------	-----	------	-------	---------	----	----------

99.1 News Release: Kamada Reports Final Results from Phase 2/3 Clinical Trial of Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency

## Edgar Filing: KAMADA LTD - Form 6-K

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 4, 2014 KAMADA LTD.

By: /s/ Gil Efron

Gil Efron

Chief Financial Officer

## Edgar Filing: KAMADA LTD - Form 6-K

#### **EXHIBIT INDEX**

# EXHIBITDESCRIPTION NO.

99.1 News Release: Kamada Reports Final Results from Phase 2/3 Clinical Trial of Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency